<p>Incidence and PD-L1 Expression of <em>MET</em> 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing

Published:2020-06 Issue: Volume:Volume 13 Page:6245-6253
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Xu Ziguang,Li Hongxia,Dong Yujie^ORCID,Cheng Peng,Luo Fang,Fu Shijun,Gao Min,Kong Lingfei,Che Nanying

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference26 articles.

1. Cancer statistics, 2018

2. Lung cancer: current therapies and new targeted treatments

3. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation

4. Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

5. Met, metastasis, motility and more

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance;npj Precision Oncology;2024-07-26

2. Diagnosis and treatment of non-small cell lung cancer (NSCLC) harboring MET Ex14 skipping: have we met the desired drug?;Translational Lung Cancer Research;2024-06

3. Clinical research progress of callisperes® of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors;Discover Oncology;2024-05-13

4. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION;British Journal of Cancer;2024-04-04

5. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations;European Journal of Cancer;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3